Moxetumomab pasudotox Biosimilar – Research Grade
ichorbio’s Moxetumomab pasudotox biosimilar is for Research Use Only (RUO) and not for therapeutic use.
ichorbio’s RUO Moxetumomab pasudotox biosimilar is available in the following sizes:
0.1mg, 5mg, 10mg, 20mg, 50mg
ichorbio regularly manufactures bulk multi-gram amounts of this biosimilar – please contact us for pricing.
Detects human CD22. This non-therapeutic antibody uses the same variable region sequence as the antibody Moxetumomab.
This recombinant protein was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
RUO Moxetumomab pasudotox biosimilar is a CD22-directed cytotoxin and is the first of this type of treatment for adults with Hairy Cell Leukemia. The drug consists of the binding fragment (Fv) of an anti-CD22 antibody fused to a toxin called PE38. This toxin is a 38 kDa fragment of Pseudomonas exotoxin A.
1.0 – 5.0 mg/ml
Sterile, preservative-free, solution in PBS. BSA and Azide free.
>95% by SDS-PAGE and HPLC
≤ 1.0 EU/mg as determined by the LAL method
Moxetumomab pasudotox biosimilar – Research Grade is stable for at least four (4) weeks when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.
Each investigator should determine their own optimal working dilution for specific applications.
ichorbio’s Moxetumomab pasudotox biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.